Table 1.
Reference | Compound | Target | Cytotoxicity (µM) | |||
---|---|---|---|---|---|---|
Ting-Chao Chou [49] | N3 | P-gp | CCRF-CEM: 13 | CCRF-CEM/VBL1000: 100 | ||
Bin [50] | Compound 35 | P-gp | L292: >100 | MDA435/LCC6: >100 | MDA435/LCC6MDR: >100 | |
Yang [45] | Compound 23 | P-gp | L292: >100 | MDA435/LCC6: >100 | MDA435/LCC6MDR: >100 | |
Wang [51] | Compound 12 | P-gp | L292: >100 | MDA435/LCC6: >100 | MDA435/LCC6MDR: >100 | |
Chen [53] | 5 Bromo-tetrandrine | P-gp | KB: 5.14 | KBv200: 6.17 | ||
Sun [54] | W6 | P-gp | KB: ~2 | KBv200: ~4 | MCF-7: ~4.5 | MCF-7/DOX: ~5 |
Zhu [55] | Compound 26 | P-gp | HepG2/ADR: >150 | MCF-7/ADR: >150 | ||
Kraege [29] | GO-Y078 | BCRP | K562/BCRP: 0.31 | |||
Wong [56] | Compound 51 | MRP1, P-gp and BCRP | L292: >100 | LCC6: >100 | LCC6MDR: >100 | |
Wong [56] | 4e | MRP1 | L292: >100 | LCC6: >100 | LCC6MDR: >100 |